HRS-9821

HRS-9821 is an investigational small molecule drug developed by Guangdong Hengrui Pharmaceutical. It is formulated as an atomized inhalation therapy and is currently in Phase 1 clinical trials for the treatment of chronic obstructive pulmonary disease (COPD). The drug acts as a dual inhibitor of type 3 and type 4 cyclic nucleotide phosphodiesterases (PDE3 and PDE4), which are enzymes involved in the regulation of airway smooth muscle tone and inflammation. By inhibiting both PDE3 and PDE4, HRS-9821 functions as a bronchodilator with potential anti-inflammatory effects, targeting respiratory diseases such as COPD[1][2][3].